Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mantle cell lymphoma
Pharma
AZ makes case for Calquence in another blood cancer type
AstraZeneca reported that adding Calquence to standard of care reduced the risk of disease progression or death by 27% in MCL patients.
Kevin Dunleavy
Jun 17, 2024 11:25am
AZ clinches early Calquence win in untreated MCL
May 2, 2024 10:24am
An Imbruvica combo regimen could have a new future in MCL
Dec 12, 2023 12:33pm
Abbvie, J&J pull 2 Imbruvica accelerated approvals
Apr 7, 2023 10:25am
Lilly wins FDA approval for 4th BTK blood cancer drug
Jan 27, 2023 3:50pm
NICE signs off on BeiGene's Brukinsa for blood cancer disorder
Sep 20, 2022 10:10am
